A PYMNTS Company

J&J to sell wrist fracture surgical system for FTC approval of Synthes buy

By  |  June 11, 2012

To allow Johnson & Johnson (J&J)’s proposed acquisition of Synthes, the Federal Trade Commission is requiring J&J sell its system for surgically treating distal radius wrist fractures. The original deal would remove Synthes, J&J’s direct rival for volar distal radius (DVR) treatment systems, from a market that is highly concentrated. J&J and Synthes have a combined U.S. market share of over 70 percent. The FTC claimed that a merger would lead to price increases for a surgical system that is widely used for wrist trauma.

J&J will sell its entire trauma portfolio, in addition to its DVR plating system, to Biomet.

Full content: FTC Press Release

 

Related content: Analyzing Medical Device Mergers

 

Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.